A recent study published in JAMA Internal Medicine examines medication patterns for older adults managing type 2 diabetes. Researchers analyzed electronic health record data from nearly 90,000 patients at the Cleveland Clinic between 2019 and 2023 to understand how treatment adjustments align with A1c levels.
The findings show that medication management varies significantly based on glycemic status. Patients with A1c levels exceeding clinical goals were more likely to see changes in their prescriptions compared to those within target ranges. While approximately 33% of those above goal received increased medication, only about 16% of patients at goal experienced similar changes.
The data also highlights a shift in deintensification practices. Researchers observed an increase in medication decreases over the study period, rising from 14.6% in 2019 to 20.3% in 2023. Interestingly, patients with A1c levels below their guideline goals showed similar rates of medication reduction as those who were at their target levels.
Despite these adjustments, the study authors point out that many older patients with A1c levels outside of recommended ranges did not receive updates to their treatment plans. This suggests a disconnect between current patient metrics and clinical practice. The authors advocate for future work to focus on stricter adherence to medical guidelines and the use of safer pharmaceutical options for this demographic.
Limitations to the research include the exclusion of insulin dose data and the reliance on a single A1c measurement per year to classify health status. These factors indicate that while medication patterns are observable, the full clinical picture remains complex for providers managing diabetes in elderly populations.